| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CFO
1 company
Dan Stokely last filed a Form 4 in January 2022, as CFO at AMPE. Dan Stokely's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 312,274 shares of AMPE. The AMPE filings lean toward selling, a net 97,500 shares.
Dan Stokely has 11 Form 4 filings on record from July 2019 to January 2022, all as CFO at Ampio Pharmaceuticals (AMPE), 2019–2022.
The 17 reported transactions were 5 option exercises, 4 option or other derivative awards, 3 tax withholdings and 3 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $177K.
The largest open-market sale was 40,000 shares of AMPE at an average $1.83 on March 16, 2021, about $73K.
Shares as reported in the last Form 4 for each company; the most recent is from January 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.